These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14660453)

  • 21. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.
    Yokoyama Y; Kawasaki R; Takahashi H; Maekawa S; Tsuda S; Omodaka K; Nakazawa T
    J Glaucoma; 2019 Jul; 28(7):575-583. PubMed ID: 31188229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Special considerations in low-tension glaucoma.
    Krupin T
    Can J Ophthalmol; 2007 Jun; 42(3):414-7. PubMed ID: 17508037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of brimonidine on patients undergoing uncontrolled IOP with beta-blockers.
    Taverniti L; Di Staso S; Arrico L; Giuffrè I; Recupero SM; ;
    Acta Ophthalmol Scand Suppl; 2002; 236():54. PubMed ID: 12390143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.
    Lee DA
    Clin Ther; 2000 Jan; 22(1):53-65. PubMed ID: 10688390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brimonidine (Alphagan): a clinical profile four years after launch.
    David R
    Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
    Lee DA; Gornbein J; Abrams C
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
    Motolko MA
    Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A; Kapik B; Shams N;
    Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
    Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
    Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normal-tension glaucoma.
    Anderson DR; Feuer W; Schiffman J
    Ophthalmology; 2008 Mar; 115(3):590-1; author reply 591-2. PubMed ID: 18319115
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
    Cantor LB; Hoop J; Katz LJ; Flartey K;
    Clin Ther; 2001 Jul; 23(7):1032-9. PubMed ID: 11519768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Contrast Sensitivity after Four Different Treatment Modalities Using OPTEC-Functional Vision Analyzer in Primary Open-Angle Glaucoma.
    Azizzadeh P; Safarzadeh M
    Middle East Afr J Ophthalmol; 2019; 26(2):60-64. PubMed ID: 31543661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial medical management of open-angle glaucoma.
    Fechtner RD
    J Glaucoma; 2000 Feb; 9(1):83-6. PubMed ID: 10708236
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.